<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; NP</title>
	<atom:link href="http://www.stockbloghub.com/tag/np/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(THRX) Theravance Third Quarter Loss Deteriorates</title>
		<link>http://www.stockbloghub.com/2011/11/02/thrx-theravance-third-quarter-loss-deteriorates/86313</link>
		<comments>http://www.stockbloghub.com/2011/11/02/thrx-theravance-third-quarter-loss-deteriorates/86313#comments</comments>
		<pubDate>Wed, 02 Nov 2011 21:01:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[FF]]></category>
		<category><![CDATA[First Opportunity Fund Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICS]]></category>
		<category><![CDATA[Morgan Stanley Insured California Municipal Securi]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86313</guid>
		<description><![CDATA[Theravance Inc.’s (THRX) third quarter 2011 loss per share of 37 cents was wider than the Zacks Consensus loss Estimate of 33 cents as well as the year-ago loss of 29 cents per share. The wider loss was attributable to a lukewarm top-line performance as well as increased research and development (R&#38;D) expenses. Revenue at Theravance though up 21.3% over the prior year to $6.4 million was below the Zacks Consensus Estimate of $7 million. The Quarter in Detail Revenues for the quarter primarily consisted of the amortization of deferred revenues received under the company’s collaborations with Astellas Pharma and GlaxoSmithKline plc (GSK). Theravance earned a royalty of $0.8 million on Vibativ sales from Astellas Pharma on net sales of $4.5 million. Vibativ, Theravance’s only commercialized drug, is an injectable ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/thrx-theravance-third-quarter-loss-deteriorates/86313/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322</link>
		<comments>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76322</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate, but narrower than the year-ago loss of 35 cents per share. Revenues at Theravance increased 10% year over year to $6.3 million. An increase in royalty revenues from Vibativ sales in the reported quarter was attributable for both the jump in revenues and the narrower year-over-year loss per share. However, total revenue was below the Zacks Consensus Revenue Estimate of $7 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253</link>
		<comments>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253#comments</comments>
		<pubDate>Tue, 14 Jun 2011 15:03:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76253</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate, but narrower than the year-ago loss of 35 cents per share. Revenues at Theravance increased 10% year over year to $6.3 million. An increase in royalty revenues from Vibativ sales in the reported quarter was attributable for both the jump in revenues and the narrower year-over-year loss per share. However, total revenue was below the Zacks Consensus Revenue Estimate of $7 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NP) Neenah Paper &#8211; Business Is Improving</title>
		<link>http://www.stockbloghub.com/2010/04/19/np-neenah-paper-business-is-improving/34208</link>
		<comments>http://www.stockbloghub.com/2010/04/19/np-neenah-paper-business-is-improving/34208#comments</comments>
		<pubDate>Mon, 19 Apr 2010 20:48:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Consumer Goods]]></category>
		<category><![CDATA[Paper & Paper Products]]></category>
		<category><![CDATA[MCO]]></category>
		<category><![CDATA[Moody's Corporation]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34208</guid>
		<description><![CDATA[Neenah Paper (NP) crushed fourth-quarter EPS estimates by 15 cents, or 79%, and management was more optimistic about 2010. Company Description Neenah Paper manufactures and distributes a wide range of premium and specialty paper grades, with well-known brands such as Classic, Environment, Kimdura, and Munising. The company also produces and sells bleached pulp, primarily for use in the manufacture of tissue and writing papers. The Zacks Rank #1 stock has a dividend yield of 2.1%. Business Is Improving Recently, management indicated that its businesses continue to gain momentum with a fourth sequential quarterly increase in sales, EBIT, and margins. The company has been able to maintain cost reduction efforts and increase selling prices. Additionally, the company is using its cash flow to pay down debt. Neenah Paper&#8217;s improved results and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/19/np-neenah-paper-business-is-improving/34208/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NP) Neenah Paper &#8211; Analysts Increase Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2010/03/03/np-neenah-paper-analysts-increase-earnings-estimates/29522</link>
		<comments>http://www.stockbloghub.com/2010/03/03/np-neenah-paper-analysts-increase-earnings-estimates/29522#comments</comments>
		<pubDate>Wed, 03 Mar 2010 23:05:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Consumer Goods]]></category>
		<category><![CDATA[Paper & Paper Products]]></category>
		<category><![CDATA[MCO]]></category>
		<category><![CDATA[Moody's Corporation]]></category>
		<category><![CDATA[Neenah Paper]]></category>
		<category><![CDATA[NP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29522</guid>
		<description><![CDATA[Neenah Paper&#8217;s (NP) recent results have been better than expected, and analysts have been raising their earnings estimates. Company Description Neenah Paper manufactures and distributes a wide range of premium and specialty paper grades, with well-known brands such as Classic, Environment, Kimdura, and Munising. The company also produces and sells bleached pulp, primarily for use in the manufacture of tissue and writing papers. Business Is Improving Management indicated that its businesses continue to gain momentum with a fourth sequential quarterly increase in sales, EBIT, and margins. The company has been able to maintain cost reduction efforts and increase selling prices. Additionally, the company is using its cash flow to pay down debt. Neenah Paper&#8217;s improved results and balance sheet caught the attention of Moody&#8217;s (MCO), which placed all of its ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/np-neenah-paper-analysts-increase-earnings-estimates/29522/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NP) Neenah Paper, Inc. &#8211; Momentum &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/06/05/np-neenah-paper-inc-momentum-zacks-rank-buy/7929</link>
		<comments>http://www.stockbloghub.com/2009/06/05/np-neenah-paper-inc-momentum-zacks-rank-buy/7929#comments</comments>
		<pubDate>Fri, 05 Jun 2009 22:15:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Consumer Goods]]></category>
		<category><![CDATA[Paper & Paper Products]]></category>
		<category><![CDATA[Neenah Paper]]></category>
		<category><![CDATA[NP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=7929</guid>
		<description><![CDATA[Neenah Paper, Inc. (NP) recently reported first-quarter results. Earnings came in 88% ahead of the consensus estimate, and analysts are bullish on earnings going forward. Management said the company is poised to grow stronger as global economies recover. Company Description Neenah Paper manufactures premium, performance-based papers and specialty products used in a variety of applications including filtration, printing and writing. The company makes well-known brands like CLASSIC®, ENVIRONMENT®, STARWHITE®, Gessner®, JET-PRO® SofStretch(TM) and varitess®. Based in Alpharetta, Georgia, Neenah Paper has manufacturing operations in the United States and Germany as well as about 500,000 acres of timberlands in Nova Scotia, Canada. A Solid Quarter The company recently reported first-quarter results. While the earnings result was actually a loss of 5 cents per share, it was 88% ahead of the consensus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/05/np-neenah-paper-inc-momentum-zacks-rank-buy/7929/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

